PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

NewMarket Pharmaceuticals LLC

USPTO PatentsView assignee record - 9 granted patents across 3 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Newmarket ranks #29,591 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 3 technology areas.

#29,591
of 49,997 US assignees by volume
22nd percentile
by Innovation Score (26.8/100)
15.7
avg claims per patent
+100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R29591 · US Corporation #29,591 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 9 grants
  • MID-PACK #29,591/49,997
  • PHOTO-FINISH Neurocentria
  • CPC-NARROW A61K · 3 areas
  • INNOV-THIN 26.8/100
  • CLAIMS-RICH 15.7 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +100% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Neurocentria, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Newmarket’s 26.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Newmarket

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Newmarket's Innovation Score is 26.8/100 (22nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Newmarket?

Each dot is one of Newmarket’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Newmarket’s own 15.7 claims/patent is at or below the 17.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Newmarket vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 8.98.999.1 0510152025 Granted patents (volume) Avg claims / patent Neurocentria, Inc. - 9, 19.44NeurocentriaNeutron Therapeutics LLC - 9, 17.56Neutron Therapeut…New Ideas Manufacturing LLC - 9, 4New Ideas Manufac…New Standards Manufacturing Co. - 9, 14.44New Standards Man…NewSight Reality, Inc. - 9, 20.89Newsight RealityNexstim Oyj - 9, 19.22Nexstim OyjNext Issue Media - 9, 20.67Next Issue MediaNfinium Vascular Technologies, LLC - 9, 15.22Nfinium VascularNewMarket Pharmaceuticals LLC - 9, 15.67Newmarket Pharmac…
Newmarket vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Newmarket's grants concentrate

NewMarket Pharmaceuticals LLC is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2016. By volume, Newmarket sits between Neurocentria, Inc. and Nfinium Vascular Technologies, LLC.

Newmarket's three-year grant acceleration

NewMarket Pharmaceuticals LLC shows 2 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at NewMarket's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows NewMarket holds 9 patents at rank #29,600, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near NewMarket

By rank, the assignees closest to #29,600 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in NewMarket's primary technology class.

Newmarket's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 22nd percentile higher than 22% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 201620182020202120232024 1
USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
NewMarket Pharmaceuticals LLC patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 1 11.1%
2018 2 22.2%
2020 2 22.2%
2021 2 22.2%
2023 1 11.1%
2024 1 11.1%

Which technologies does NewMarket Pharmaceuticals LLC patent most?

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

NewMarket Pharmaceuticals LLC's patent record in context - here's where to go next.

  • NewMarket Pharmaceuticals LLC's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #29,591 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare NewMarket Pharmaceuticals LLC against Neurocentria, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 26.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.